Abbvie (HARBOR) Study
Additional Information
Description – An investigational drug for adults who are showing signs of early Alzheimer’s disease or have been diagnosed with early Alzheimer’s.
Participants – Mild Cognitive Impairment / Alzheimer's Disease (MCI/AD): Have shown signs of early Alzheimer’s or have been diagnosed with early Alzheimer’s.
Age – 50 to 90 years of age.
Duration/Visits – Phase II double blind for 6 months, then open label for 18 months. Weekly, biweekly, and monthly visits.
Prinicipal Investigator – Dr. Michael Borrie, Parkwood Institute.
Research Coordinator – Kayla VanderPloeg
- Phone: (519) 685-4292 ext. 42255
- Please contact Kayla for more information about this study.
AHEAD (A3/A-45) Study
Additional Information
Description – Worried about your memory? The AHEAD Study is recruiting individuals as young as 55 and tests whether an investigational treatment may help prevent Alzheimer's. Visit their website to learn more.
Participants – Subjective Cognitive Impairment (SCI).
Age – 55-80 years (age 55 to 64 MUST have 1 other risk factor ie. Family hx of 1st degree relative/amyloid/APOE).
Duration/Visits – 216 weeks (A3- monthly infusion, A45 – every 2 weeks infusion until week 96, then monthly).
Prinicipal Investigator – Dr. Jaspreet Bhangu, Parkwood Institute.
Research Coordinator – Rebecca Shostak
- Phone: (519) 685-4292 ext. 45609
- Email: Rebecca.shostak@sjhc.london.on.ca
- Please contact Rebecca for more information about this study.
